AR016399A1 - Composiciones farmaceuticas, composiciones farmaceuticas para uso con una segunda composicion para obtener una mejora en el efecto terapeutico, un kit quelas contiene y uso de un compuesto para preparar la composicion - Google Patents

Composiciones farmaceuticas, composiciones farmaceuticas para uso con una segunda composicion para obtener una mejora en el efecto terapeutico, un kit quelas contiene y uso de un compuesto para preparar la composicion

Info

Publication number: AR016399A1
Authority: AR; Argentina
Prior art keywords: compositions; pharmaceutical compositions; composition; antihypertensive agents; kit
Prior art date: 1997-08-29

Application number

ARP980104287A

Other languages

English (en)

Spanish (es)

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-29

Filing date

1998-08-27

Publication date

2001-07-04

1998-08-27 Application filed by Pfizer filed Critical Pfizer

2001-07-04 Publication of AR016399A1 publication Critical patent/AR016399A1/es

Links

239000000203 mixture Substances 0.000 title abstract 7
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
239000002220 antihypertensive agent Substances 0.000 abstract 3
229940030600 antihypertensive agent Drugs 0.000 abstract 3
206010002383 Angina Pectoris Diseases 0.000 abstract 2
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 2
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 2
208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
206010020772 Hypertension Diseases 0.000 abstract 2
229960005370 atorvastatin Drugs 0.000 abstract 2
230000000747 cardiac effect Effects 0.000 abstract 2
208000024891 symptom Diseases 0.000 abstract 2
230000002195 synergetic effect Effects 0.000 abstract 2
239000005541 ACE inhibitor Substances 0.000 abstract 1
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
241000282412 Homo Species 0.000 abstract 1
241000282414 Homo sapiens Species 0.000 abstract 1
239000000654 additive Substances 0.000 abstract 1
230000000996 additive effect Effects 0.000 abstract 1
102000004305 alpha Adrenergic Receptors Human genes 0.000 abstract 1
108090000861 alpha Adrenergic Receptors Proteins 0.000 abstract 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
238000003149 assay kit Methods 0.000 abstract 1
102000012740 beta Adrenergic Receptors Human genes 0.000 abstract 1
108010079452 beta Adrenergic Receptors Proteins 0.000 abstract 1
239000000480 calcium channel blocker Substances 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
229940030606 diuretics Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940124549 vasodilator Drugs 0.000 abstract 1
239000003071 vasodilator agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrrole Compounds (AREA)
Iron Core Of Rotating Electric Machines (AREA)

ARP980104287A 1997-08-29 1998-08-27 Composiciones farmaceuticas, composiciones farmaceuticas para uso con una segunda composicion para obtener una mejora en el efecto terapeutico, un kit quelas contiene y uso de un compuesto para preparar la composicion AR016399A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5727697P	1997-08-29	1997-08-29

Publications (1)

Publication Number	Publication Date
AR016399A1 true AR016399A1 (es)	2001-07-04

Family

ID=22009602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP980104287A AR016399A1 (es)	1997-08-29	1998-08-27	Composiciones farmaceuticas, composiciones farmaceuticas para uso con una segunda composicion para obtener una mejora en el efecto terapeutico, un kit quelas contiene y uso de un compuesto para preparar la composicion

Country Status (41)

Country	Link
US (2)	US20020099046A1 (fr)
EP (1)	EP1009400B1 (fr)
JP (2)	JP2001514223A (fr)
KR (3)	KR20040106591A (fr)
CN (3)	CN1473566A (fr)
AP (1)	AP1191A (fr)
AR (1)	AR016399A1 (fr)
AT (1)	ATE285767T1 (fr)
AU (1)	AU740424B2 (fr)
BG (1)	BG64724B1 (fr)
BR (1)	BR9811556A (fr)
CA (1)	CA2296723A1 (fr)
CO (1)	CO4970724A1 (fr)
DE (1)	DE69828413T2 (fr)
DZ (1)	DZ2595A1 (fr)
EA (1)	EA200000012A1 (fr)
EG (1)	EG24678A (fr)
ES (1)	ES2234134T3 (fr)
GT (1)	GT199800126A (fr)
HR (1)	HRP980474A2 (fr)
HU (1)	HUP0004318A3 (fr)
ID (1)	ID24118A (fr)
IL (2)	IL133962A0 (fr)
IS (1)	IS5341A (fr)
MA (1)	MA26536A1 (fr)
MY (1)	MY121008A (fr)
NO (1)	NO323987B1 (fr)
NZ (2)	NZ502280A (fr)
OA (1)	OA11291A (fr)
PA (1)	PA8457901A1 (fr)
PE (1)	PE107099A1 (fr)
PL (1)	PL339091A1 (fr)
PT (1)	PT1009400E (fr)
SA (1)	SA98190603B1 (fr)
SK (1)	SK1432000A3 (fr)
TN (1)	TNSN98155A1 (fr)
TR (1)	TR200000563T2 (fr)
UY (1)	UY25155A1 (fr)
WO (1)	WO1999011260A1 (fr)
YU (1)	YU2000A (fr)
ZA (1)	ZA987839B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE40792E1 (en)	1992-05-19	2009-06-23	Novogen Research Pty Ltd	Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en)	1996-08-30	1996-09-26	Novogen Research Pty Ltd	Therapeutic uses
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.
NZ505994A (en) *	1998-03-17	2003-10-31	Warner Lambert Co	Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases
DK1140184T3 (da)	1998-12-23	2003-09-29	Searle Llc	Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
AU2007200367B2 (en) *	1999-02-06	2010-04-08	Astrazeneca Ab	Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en)	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
HUP0203326A3 (en)	1999-08-30	2003-04-28	Sanofi Aventis Deutschland	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
AUPQ266199A0 (en)	1999-09-06	1999-09-30	Novogen Research Pty Ltd	Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) *	1999-09-20	2001-03-29	Bayer Ag	Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
ATE309807T1 (de)	1999-09-24	2005-12-15	Vasogen Ireland Ltd	Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält
FR2803525B1 (fr) *	2000-01-06	2002-05-03	Sod Conseils Rech Applic	Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) *	2000-04-03	2003-08-20	Astrazeneca Ab	Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en)	2000-04-10	2001-10-17	Nicholas J Wald	Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) *	2000-06-22	2000-06-22	Astrazeneca Ab	New formulation
BR0112665A (pt)	2000-07-19	2003-06-24	Novartis Ag	Sais
AU2001284413A1 (en) *	2000-08-30	2002-03-13	Sankyo Company Limited	Medicinal compositions for preventing or treating heart failure
US7018649B2 (en) *	2000-10-23	2006-03-28	Euro-Celtique, S.A.	Felodipine transdermal device and methods
US8168616B1 (en)	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
AUPR255401A0 (en) *	2001-01-16	2001-02-08	Novogen Research Pty Ltd	Regulation of lipids and/or bone density and compositions therefor
PT1355644E (pt)	2001-01-26	2006-11-30	Schering Corp	Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
RS20100015A (sr)	2001-01-26	2010-12-31	Schering Corporation	Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AUPR363301A0 (en)	2001-03-08	2001-04-05	Novogen Research Pty Ltd	Dimeric isoflavones
ATE363917T1 (de) *	2001-07-19	2007-06-15	Pharmacia Corp	Kombination von einem aldosterone rezeptor antagonisten und einem hmg coa reduktase hemmer
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en)	2001-08-06	2005-02-08	Recordati Ireland Limited	Crude and crystalline forms of lercanidipine hydrochloride
EP1429756B1 (fr)	2001-09-21	2006-11-22	Schering Corporation	Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US8101209B2 (en)	2001-10-09	2012-01-24	Flamel Technologies	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003207431A1 (en)	2002-01-17	2003-09-02	Pharmacia Corporation	Novel alkyl/aryl hydroxy or keto thiepines.
ATE395936T1 (de) *	2002-06-20	2008-06-15	Univ Alberta	Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
MXPA04012923A (es) *	2002-06-27	2005-03-31	Sb Pharmco Inc	Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
AU2003251627A1 (en) *	2002-06-27	2004-01-19	Sb Pharmco Puerto Rico Inc.	Carvedilol hydrobromide
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0221579D0 (en) *	2002-09-17	2002-10-23	Pfizer Ltd	Combinations of atorvastatin and, adrenergic receptor antagonists
WO2004035051A1 (fr) *	2002-10-16	2004-04-29	Recordati Ireland Limited	Polytherapie a base de lisinopril/lercanidipine
JP2006508188A (ja)	2002-11-06	2006-03-09	シェーリング　コーポレイション	脱髄の処置のためのコレステロール吸収インヒビター
CN1756755A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004016123D1 (de)	2003-03-07	2008-10-09	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756756A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
WO2005051322A2 (fr) *	2003-11-25	2005-06-09	Sb Pharmco Puerto Rico Inc.	Base libre de carvedilol, ses sels, formes anhydres ou solvates, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et procedes de traitement ou d'administration
JP2007512372A (ja) *	2003-11-25	2007-05-17	エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド	カルベジロール塩、対応する組成物、送達および／または治療方法
US20050169994A1 (en) *	2003-11-25	2005-08-04	Burke Matthew D.	Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
KR20050092519A (ko) *	2004-03-16	2005-09-22	화이자 인코포레이티드	아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
US20070191438A1 (en) *	2004-04-06	2007-08-16	Rohrer Susan P	Methods for the treatment of hypertension
CA2568640C (fr)	2004-06-04	2011-08-09	Teva Pharmaceutical Industries Ltd.	Composition pharmaceutique contenant de l'irbesartan
CN104958270A (zh) *	2004-08-25	2015-10-07	伊森舍丽斯有限公司	钾atp通道开放剂的药物制剂及其应用
CA2597498A1 (fr) *	2005-02-17	2006-08-24	Chiesi Farmaceutici S.P.A.	Combinaisons therapeutiques de manidipine et d'une statine
JP5330825B2 (ja) *	2006-03-29	2013-10-30	興和株式会社	トリグリセリド低下剤及び高インスリン血症改善剤
US8642083B2 (en) *	2006-10-30	2014-02-04	Hanall Biopharma Co., Ltd.	Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
US20110117194A1 (en)	2008-04-29	2011-05-19	Hanall Biopharma Co., Ltd.	Pharmaceutical formulation containing angiotensin-ii receptor blocker
CZ2008740A3 (cs) *	2008-11-24	2010-01-06	Zentiva, A.S.	Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
JP5658172B2 (ja) *	2009-01-23	2015-01-21	ハンミ・サイエンス・カンパニー・リミテッド	アムロジピン及びロサルタンを含む固形薬剤学的組成物及びその製造方法
SI23149A (sl) *	2009-09-21	2011-03-31	Silverstone Pharma	Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) *	2011-10-27	2013-05-10	Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ"	Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) *	2011-12-17	2012-09-19	东莞达信生物技术有限公司	一种降压降脂复方药及其制备方法
KR20140028971A (ko) *	2012-08-31	2014-03-10	한미약품 주식회사	아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
WO2014142521A1 (fr) *	2013-03-12	2014-09-18	주식회사 엘지생명과학	Préparation de complexe comportant du valsartan et de la rosuvastatine calcique et procédé de fabrication correspondant
CN104173420A (zh) *	2013-05-20	2014-12-03	广州诺氏刘生物科技有限公司	一种治疗急性肾衰竭的药物
MX394186B (es)	2014-10-23	2025-03-24	Arena Pharm Inc	Metodo de tratamiento de afecciones relacionadas con el receptor pgi2
CN108156807A (zh) *	2015-06-30	2018-06-12	韩美药品株式会社	含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
FR3040303B1 (fr) *	2015-08-27	2019-04-05	Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger	Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) *	2015-11-19	2016-01-13	哈尔滨圣吉药业股份有限公司	一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
MX2018014933A (es) *	2016-06-02	2019-04-09	Ana Pharmaceuticals Inc	Metodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis.
DK4101454T3 (da)	2017-01-25	2024-06-17	The George Inst For Global Health	Sammensætninger til behandling af hypertension
US12521380B2 (en)	2017-01-25	2026-01-13	The George Institute for Global Health	Compositions for the treatment of hypertension
EP3977985B1 (fr)	2017-03-01	2023-09-06	Arena Pharmaceuticals, Inc.	Compositions comprenant des agonistes du récepteur pgi2 et procédés de préparation associés
KR20210040837A (ko)	2018-05-16	2021-04-14	아레나 파마슈티칼스, 인크.	Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
KR20210038931A (ko) *	2018-07-26	2021-04-08	더 조지 인스티튜트 포 글로벌 헬스	고혈압 치료용 조성물
CN112826937B (zh) *	2021-03-25	2022-03-22	山东大学齐鲁医院	艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4681893A (en) *	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) *	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) *	1994-08-24	1995-09-05	Bristol-Myers Squibb Company	α-phosphonosulfinic squalene synthetase inhibitors
US5798375A (en) *	1995-07-03	1998-08-25	Sankyo Company, Limited	Treatment of arteriosclerosis and xanthoma
CN1217656C (zh) *	1995-11-02	2005-09-07	沃尼尔·朗伯公司	用于调节脂浓度的方法和药物组合物

1998
- 1998-08-07 GT GT199800126A patent/GT199800126A/es unknown
- 1998-08-11 KR KR10-2004-7019432A patent/KR20040106591A/ko not_active Ceased
- 1998-08-11 HU HU0004318A patent/HUP0004318A3/hu unknown
- 1998-08-11 AU AU84589/98A patent/AU740424B2/en not_active Ceased
- 1998-08-11 EA EA200000012A patent/EA200000012A1/ru unknown
- 1998-08-11 BR BR9811556-1A patent/BR9811556A/pt not_active Application Discontinuation
- 1998-08-11 PT PT98935250T patent/PT1009400E/pt unknown
- 1998-08-11 EP EP98935250A patent/EP1009400B1/fr not_active Expired - Lifetime
- 1998-08-11 SK SK143-2000A patent/SK1432000A3/sk unknown
- 1998-08-11 JP JP2000508363A patent/JP2001514223A/ja not_active Withdrawn
- 1998-08-11 TR TR2000/00563T patent/TR200000563T2/xx unknown
- 1998-08-11 AT AT98935250T patent/ATE285767T1/de not_active IP Right Cessation
- 1998-08-11 CN CNA031430929A patent/CN1473566A/zh active Pending
- 1998-08-11 CN CNA031430937A patent/CN1473567A/zh active Pending
- 1998-08-11 KR KR10-2003-7000672A patent/KR20030015394A/ko not_active Ceased
- 1998-08-11 ES ES98935250T patent/ES2234134T3/es not_active Expired - Lifetime
- 1998-08-11 WO PCT/IB1998/001230 patent/WO1999011260A1/fr not_active Ceased
- 1998-08-11 NZ NZ502280A patent/NZ502280A/xx unknown
- 1998-08-11 ID IDW20000196A patent/ID24118A/id unknown
- 1998-08-11 KR KR1020007001062A patent/KR20010022477A/ko not_active Ceased
- 1998-08-11 CA CA002296723A patent/CA2296723A1/fr not_active Abandoned
- 1998-08-11 CN CN98808463A patent/CN1268053A/zh active Pending
- 1998-08-11 NZ NZ530630A patent/NZ530630A/en unknown
- 1998-08-11 IL IL13396298A patent/IL133962A0/xx not_active IP Right Cessation
- 1998-08-11 YU YU2000A patent/YU2000A/sh unknown
- 1998-08-11 DE DE69828413T patent/DE69828413T2/de not_active Expired - Fee Related
- 1998-08-11 PL PL98339091A patent/PL339091A1/xx unknown
- 1998-08-17 PA PA19988457901A patent/PA8457901A1/es unknown
- 1998-08-24 PE PE1998000769A patent/PE107099A1/es not_active Application Discontinuation
- 1998-08-26 MA MA25228A patent/MA26536A1/fr unknown
- 1998-08-26 UY UY25155A patent/UY25155A1/es not_active Application Discontinuation
- 1998-08-26 DZ DZ980205A patent/DZ2595A1/fr active
- 1998-08-26 TN TNTNSN98155A patent/TNSN98155A1/fr unknown
- 1998-08-27 MY MYPI98003941A patent/MY121008A/en unknown
- 1998-08-27 EG EG102598A patent/EG24678A/xx active
- 1998-08-27 AR ARP980104287A patent/AR016399A1/es unknown
- 1998-08-27 CO CO98049139A patent/CO4970724A1/es unknown
- 1998-08-27 AP APAP/P/1998/001332A patent/AP1191A/en active
- 1998-08-28 ZA ZA9807839A patent/ZA987839B/xx unknown
- 1998-08-28 HR HR60/057,276A patent/HRP980474A2/hr not_active Application Discontinuation
- 1998-09-30 SA SA98190603A patent/SA98190603B1/ar unknown
2000
- 2000-01-09 IL IL133962A patent/IL133962A/en unknown
- 2000-01-13 BG BG104075A patent/BG64724B1/bg unknown
- 2000-01-14 IS IS5341A patent/IS5341A/is unknown
- 2000-02-18 OA OA1200000040A patent/OA11291A/en unknown
- 2000-02-28 NO NO20000996A patent/NO323987B1/no unknown
2001
- 2001-10-23 US US10/045,329 patent/US20020099046A1/en not_active Abandoned
2003
- 2003-05-19 US US10/442,285 patent/US20030199492A1/en not_active Abandoned
2004
- 2004-07-22 JP JP2004214382A patent/JP2005041875A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE69828413T2 (de)	2005-12-08
DZ2595A1 (fr)	2003-02-22
WO1999011260A1 (fr)	1999-03-11
CN1473567A (zh)	2004-02-11
GT199800126A (es)	2000-01-29
YU2000A (sh)	2002-12-10
MA26536A1 (fr)	2004-12-20
EP1009400A1 (fr)	2000-06-21
ZA987839B (en)	2000-02-28
PE107099A1 (es)	1999-11-06
NO323987B1 (no)	2007-07-30
CN1473566A (zh)	2004-02-11
MY121008A (en)	2005-12-30
KR20040106591A (ko)	2004-12-17
CO4970724A1 (es)	2000-11-07
KR20010022477A (ko)	2001-03-15
EA200000012A1 (ru)	2000-08-28
NO20000996L (no)	2000-04-27
BR9811556A (pt)	2000-08-22
HUP0004318A2 (hu)	2001-05-28
UY25155A1 (es)	2000-12-29
US20030199492A1 (en)	2003-10-23
US20020099046A1 (en)	2002-07-25
IS5341A (is)	2000-01-14
BG104075A (en)	2000-09-29
AP9801332A0 (en)	1998-09-30
NZ502280A (en)	2002-11-26
PL339091A1 (en)	2000-12-04
TNSN98155A1 (fr)	2005-03-15
CN1268053A (zh)	2000-09-27
IL133962A (en)	2006-07-05
CA2296723A1 (fr)	1999-03-11
NO20000996D0 (no)	2000-02-28
ATE285767T1 (de)	2005-01-15
KR20030015394A (ko)	2003-02-20
EP1009400B1 (fr)	2004-12-29
ES2234134T3 (es)	2005-06-16
AU8458998A (en)	1999-03-22
HRP980474A2 (en)	1999-06-30
OA11291A (en)	2003-08-25
PA8457901A1 (es)	2000-05-24
PT1009400E (pt)	2005-02-28
BG64724B1 (bg)	2006-01-31
NZ530630A (en)	2005-05-27
SK1432000A3 (en)	2000-12-11
TR200000563T2 (tr)	2000-07-21
JP2005041875A (ja)	2005-02-17
AP1191A (en)	2003-07-19
EG24678A (en)	2010-04-27
HUP0004318A3 (en)	2002-10-28
IL133962A0 (en)	2001-04-30
SA98190603B1 (ar)	2006-07-04
DE69828413D1 (de)	2005-02-03
AU740424B2 (en)	2001-11-01
JP2001514223A (ja)	2001-09-11
ID24118A (id)	2000-07-06

Legal Events

Date	Code	Title	Description
2010-05-13	FB	Suspension of granting procedure

Publication	Publication Date	Title
UY25155A1 (es)	2000-12-29	Composiciones farmacéuticas conteniendo atorvastatina y un agente antihipertensivo
AR012269A1 (es)	2000-09-27	COMPOSICIoN FARMACÉUTICA Y USO DE LA MISMA PARA LA FABRICACIoN DE MEDICAMENTOS
AR034925A1 (es)	2004-03-24	Composiciones farmaceuticas de amlodipina y atorvastatina
CY1120313T1 (el)	2019-07-10	Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
PT948527E (pt)	2002-11-29	Novos derivados de ciclosporina sua preparacao e composicoes farmaceuticas que os contem
GT199700009AA (es)	1999-01-23	Terapia combinada para la osteoporosis
AR017514A1 (es)	2001-09-12	Composicion farmaceutica, una primera composicion para usarse como una segunda composicion, un estuche, procedimiento para tratar un mamifero
PT951474E (pt)	2002-11-29	Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
CY2607B2 (en)	2010-04-28	Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanylcyclyse agonists
HN1998000157A (es)	1999-06-02	Agonistas de prostaglandinas
BR9809848A (pt)	2000-06-27	Composição
ES2173294T3 (es)	2002-10-16	Nuevo uso medico.
PT817625E (pt)	2003-10-31	Composicoes para o tratamento de pele fotodanificada, compreendendo um antagonista de rar-alfa e um retinoide multi-selectivo
PA8495701A1 (es)	2001-12-14	Profarmacos mutuos de amlodipino y atorvastatina
ES2140672T3 (es)	2000-03-01	Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
ECSP982647A (es)	1999-02-22	Terapia de combinacion
ECSP982646A (es)	1999-02-22	Combinaciones terapeuticas
UY27510A1 (es)	2004-05-31	Terapia de combinación
ECSP982645A (es)	1999-02-22	Terapia de combinacion
AR018825A1 (es)	2001-12-12	Antagonistas del receptor de bradiquinina no peptidica para uso en el tratamiento de trastornos y enfermedades oftalmicas
AR044095A1 (es)	2005-08-24	Composicion farmaceutica que comprende un antagonista del receptor de la hormona del crecimiento y un antihipertensivo y uso de los mismos para prepararla
ECSP003493A (es)	2001-12-28	Profarmacos mutuos de amlodipino y atorvastatina
MX9301870A (es)	1994-05-31	Antagonistas receptores de angiotensina ii